Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal...
Main Authors: | Nanda K, Moss AC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-07-01
|
Series: | Clinical Pharmacology : Advances and Applications |
Online Access: | http://www.dovepress.com/update-on-the-management-of-ulcerative-colitis-treatment-and-maintenan-a10508 |
Similar Items
-
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
by: Nanda K, et al.
Published: (2013-01-01) -
Once-Daily MMX Mesalamine in the Management of Ulcerative colitis
by: Wojciech Blonski, et al.
Published: (2011-01-01) -
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
by: Daniel B Zandman, et al.
Published: (2009-03-01) -
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
by: Glen A Doherty, et al.
Published: (2009-12-01) -
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials
by: Pierce D, et al.
Published: (2014-05-01)